



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Imprecision of high-sensitivity cardiac troponin assays at the female 99th-percentile

Citation for published version:

Kavsak, PA, Clark, L, Arnoldo, S, Lou, A, Shea, JL, Eintracht, S, Lyon, AW, Bhayana, V, Thorlacius, L, Raizman, JE, Tsui, A, Djiana, R, Chen, M, Huang, Y, Haider, A, Booth, RA, Mccudden, C, Yip, PM, Beriault, DR, Blank, D, Fung, AWS, Taher, J, St-Cyr, J, Sharif, S, Belley-cote, E, Abramson, BL, Friedman, SM, Cox, JL, Sivilotti, MLA, Chen-Tournoux, A, McLaren, J, Mak, S, Thiruganasambandamoorthy, V, Scheuermeyer, F, Humphries, KH, Worster, A, Ko, D, Aakre, KM, Mills, NL & Jaffe, AS 2024, 'Imprecision of high-sensitivity cardiac troponin assays at the female 99th-percentile', *Clinical Biochemistry*, vol. 125, 110731. <https://doi.org/10.1016/j.clinbiochem.2024.110731>

Digital Object Identifier (DOI):

[10.1016/j.clinbiochem.2024.110731](https://doi.org/10.1016/j.clinbiochem.2024.110731)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Clinical Biochemistry

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Imprecision of high-sensitivity cardiac troponin assays at the female 99th-percentile

Peter A. Kavsak^{a,*}, Lorna Clark^a, Saranya Arnoldo^b, Amy Lou^c, Jennifer L. Shea^d, Shaun Eintracht^e, Andrew W. Lyon^f, Vipin Bhayana^g, Laurel Thorlacius^h, Joshua E. Raizmanⁱ, Albert Tsuiⁱ, Rose Djiana^e, Michael Chen^j, Yun Huang^k, Ali Haider^k, Ronald A. Booth^l, Chris McCudden^l, Paul M. Yip^b, Daniel Beriault^b, David Blank^e, Angela W.S. Fung^j, Jennifer Taher^b, Julie St-Cyr^e, Sameer Sharif^a, Emilie Belley-Cote^a, Beth L. Abramson^b, Steven M. Friedman^b, Jafna L. Cox^c, Marco L.A. Sivilotti^k, Annabel Chen-Tournoux^e, Jesse McLaren^b, Susanna Mak^b, Venkatesh Thiruganasambandamoorthy^l, Frank Scheuermeyer^j, Karin H. Humphries^j, Andrew Worster^a, Dennis Ko^b, Kristin M. Aakre^{m,n}, Nicholas L. Mills^o, Allan S. Jaffe^p

^a McMaster University, Hamilton, ON, Canada

^b University of Toronto, Toronto, ON, Canada

^c Dalhousie University, Halifax, NS, Canada

^d Saint John Regional Hospital, Saint John, NB, Canada

^e McGill University, Montréal, QC, Canada

^f University of Saskatchewan, Saskatoon, SK, Canada

^g Western University, London, ON, Canada

^h University of Manitoba, Winnipeg, MB, Canada

ⁱ University of Alberta, Edmonton, AB, Canada

^j University of British Columbia, Vancouver, BC, Canada

^k Queen's University, Kingston, ON, Canada

^l University of Ottawa, Ottawa, ON, Canada

^m Institute of Clinical Science, University of Bergen, Bergen, Norway

ⁿ Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway

^o BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

^p Mayo Clinic and Medical Center, Rochester, MN, United States

ARTICLE INFO

Keywords:

Imprecision

Female 99th percentile

Upper reference limit

High-sensitivity cardiac troponin

ABSTRACT

Background: An analytical benchmark for high-sensitivity cardiac troponin (hs-cTn) assays is to achieve a coefficient of variation (CV) of $\leq 10.0\%$ at the 99th percentile upper reference limit (URL) used for the diagnosis of myocardial infarction. Few prospective multicenter studies have evaluated assay imprecision and none have determined precision at the female URL which is lower than the male URL for all cardiac troponin assays.

Methods: Human serum and plasma matrix samples were constructed to yield hs-cTn concentrations near the female URLs for the Abbott, Beckman, Roche, and Siemens hs-cTn assays. These materials were sent (on dry ice) to 35 Canadian hospital laboratories ($n = 64$ instruments evaluated) participating in a larger clinical trial, with instructions for storage, handling, and monthly testing over one year. The mean concentration, standard deviation, and CV for each instrument type and an overall pooled CV for each manufacturer were calculated.

Results: The CVs for all individual instruments and overall were $\leq 10.0\%$ for two manufacturers (Abbott CV_{pooled} = 6.3% and Beckman CV_{pooled} = 7.0%). One of four Siemens Atellica instruments yielded a CV $> 10.0\%$ (CV_{pooled} = 7.7%), whereas 15 of 41 Roche instruments yielded CVs $> 10.0\%$ at the female URL of 9 ng/L used worldwide (6 cobas e411, 1 cobas e601, 4 cobas e602, and 4 cobas e801) (CV_{pooled} = 11.7%). Four Roche

* Corresponding author at: Juravinski Hospital and Cancer Centre, 711 Concession St, Hamilton, ON L8V 1C3, Canada.

E-mail address: kavsakp@mcmaster.ca (P.A. Kavsak).

<https://doi.org/10.1016/j.clinbiochem.2024.110731>

Received 7 December 2023; Received in revised form 2 February 2024; Accepted 8 February 2024

Available online 13 February 2024

0009-9120/© 2024 The Author(s). Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

instruments also yielded CVs > 10.0 % near the female URL of 14 ng/L used in the United States ($CV_{\text{pooled}} = 8.5\%$).

Conclusions: The number of instruments achieving a CV ≤ 10.0 % at the female 99th-percentile URL varies by manufacturer and by instrument. Monitoring assay precision at the female URL is necessary for some assays to ensure optimal use of this threshold in clinical practice.

1. Introduction

Since the first universal definition of myocardial infarction (MI) in 2000, acceptable imprecision for cardiac troponin (cTn) at the 99th-percentile of a healthy population (upper reference limit, URL) has been defined as a coefficient of variation (CV) ≤ 10 % [1]. Over the ensuing decade, improvements in the analytical performance of cTn assays led to the development of the high-sensitivity cTn (hs-cTn) assays [2]. The most recent laboratory recommendations for hs-cTn assays emphasize the importance of sex-specific 99th-percentile URLs [3,4].

Regarding monitoring assay performance, the only recommendations are to use quality control (QC) material at a concentration below the lower sex-specific URL and another concentration close to the highest sex-specific URL [3]. Monitoring performance near the lower limit of reporting (i.e., quantification within the normal range) for the hs-cTn assays has been a focus, with imprecision near the limit of detection being prospectively assessed in a clinical trial [5]. Specifically, this trial made use of a national QC program on the Abbott ARCHITECT to monitor the inter-laboratory variation using a patient serum pool with 3.5 ng/L of cTnI during the study [5]. Our objective was to prospectively assess the imprecision at the female URL in hospital sites across Canada as part of a randomized controlled study evaluating the impact of implementing the female URL on clinical outcomes (hs-cTn—Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI) trial; NCT03819894) [6].

2. Methods

2.1. Material for monitoring imprecision at the Female URL

The manufacturer stated female 99th URLs for hs-cTn are 16 ng/L for Abbott, 12 ng/L for Beckman, 39 ng/L for Siemens (ATELLICA and ADVIA Centaur) and 9 ng/L or 14 ng/L for Roche outside or inside the United States (US), respectively. Serum was chosen as the base material as this is an acceptable and approved sample type for all hs-cTn assays listed above, except for Abbott and Roche in the US where plasma is recommended by the manufacturer (<https://ifcc.org/ifcc-education-division/emd-committees/committee-on-clinical-applications-of-cardiac-bio-markers-c-cb/biomarkers-reference-tables/> see v052023). The serum base material was purchased from Millipore/Sigma (Product# H6914; 5x100 ml bottles) and was stored frozen (-20 °C) prior to use. For each diagnostic company (Abbott, Beckman, Roche, Siemens), a 100 ml bottle was thawed at 4 °C overnight, brought to room temperature and mixed (swirled by hand) prior to testing the serum base with the hs-cTn assay (n = 3 measurements). The Abbott hs-cTnI (ARCHITECT i1000, manufacturer's 20 %CV = 1.3 ng/L) yielded a mean value of 2.2 ng/L, the Beckman hs-cTnI (Access 2, manufacturer's 20 %CV = 1.0–2.3 ng/L) a mean of 1.5 ng/L, the Roche hs-cTnT (cobas e602, manufacturer's 20 %CV = 6 ng/L) a mean of 3.9 ng/L, and the Siemens hs-cTnI (ADVIA Centaur, manufacturer's 20 %CV = 2.5 ng/L) with all results < 2.5 ng/L (note the 20 %CV estimates were obtained from the IFCC website: High-Sensitivity Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer v052023 – see above).

Concurrent to this, high cTn plasma pools (EDTA plasma Pools A, B used previously to construct QC materials for the Abbott hs-cTnI assay where several different patients' EDTA plasma with cTnI values above 40,000 ng/L were pooled together) [7,8] were thawed at room temperature, mixed, and centrifuged (3000g for 10 min) prior to testing for

all hs-cTn assays. Pool A was used for Abbott (hs-cTnI = 42011 ng/L) as the spike material and Pool B for Roche (hs-cTnT = 9052 ng/L), for Beckman (hs-cTnI = 70304 ng/L) and for Siemens (hs-cTnI = 82996 ng/L) as the spike material. The respective high cTn pools (i.e., spike materials) were then added to the human serum base material until the desired concentration was obtained (i.e., ±20 % from the manufacturer's stated URL). The final Abbott concentration was 14.1 ng/L, Beckman concentration was 9.8 ng/L, Roche concentration was 9.0 ng/L, and Siemens concentration was 37.1 ng/L [9]. The respective female URL materials were then aliquoted into cryovials with the first (Abbott 13.7, Beckman 9.5, Roche 8.7, Siemens 36.3 ng/L) and last (Abbott 13.4, Beckman 9.8, Roche 8.6, Siemens 36.7 ng/L) cryovial tested to confirm stability and the hs-cTn concentrations of the aliquots prior to storage below -70 °C. For Roche hs-cTnT at the US female URL (14 ng/L), a previous plasma pool (12.4 ng/L) was also assessed. Stability of cTn in this material has been demonstrated [7–9].

2.2. Testing of female URL materials at clinical laboratories

The respective female URL aliquots were sent on dry ice to clinical laboratories across Canada for testing to occur once per month in the 2022 calendar year. Instructions that were provided are listed in the online Method Supplement. Testing occurred for the Abbott hs-cTnI assay in Ontario (2 Alinity, 3 ARCHITECT i2000, 1 ARCHITECT i1000 instruments) and in Saskatchewan (2 Alinity and 2 ARCHITECT i2000 instruments); for the Beckman hs-cTnI assay in Ontario (2 Dxi 600 instruments), in Quebec (1 Access 2, 1 Dxi 600, 4 Dxi 800 instruments) and in Alberta (1 Dxi 800 instrument); for the Siemens hs-cTnI assay in Ontario (4 Atellica instruments); and for the Roche hs-cTnT assay in Ontario (4 cobas e602, 8 e801 instruments), in Quebec (2 cobas e411, 4 e602 instruments), in Nova Scotia (5 cobas e411 instruments), in New Brunswick (4 cobas e602), in Manitoba (1 cobas e411, 1 e601, 2 e602 instruments), in Saskatchewan (4 cobas e801 instruments), in Alberta (2 cobas e801 instruments) and in British Columbia (1 cobas e411 and 3 cobas e601 instruments). The mean, SD, and CV were determined for each individual instrument and overall for the hs-cTn assay with the pooled CV calculated (using mean and SD with one decimal place; see Supplemental Tables).

As this was a laboratory quality assurance study assessing imprecision at the female URL using non-identifiable human material, research ethics board approval was not required.

3. Results

The CVs for all individual instruments and overall were ≤ 10.0 % for the Abbott ($CV_{\text{pooled}} = 6.3\%$; n = 10), and Beckman ($CV_{\text{pooled}} = 7.0\%$; n = 9) hs-cTnI assays. The mean concentrations ranged from 11.5 to 13.1 ng/L for the Abbott hs-cTnI assay and from 10.6 to 12.3 ng/L for the Beckman hs-cTnI assay. For the Siemens Atellica instruments (n = 4), the mean concentrations ranged from 33.2 to 34.8 ng/L, with one instrument having a CV > 10.0 % (12.3 %), with the overall $CV_{\text{pooled}} = 7.7\%$ (Fig. 1; Supplemental Table 1). Of the 41 Roche instruments, there were 15 instruments with CVs > 10.0 % on the serum sample (6 cobas e411, 1 cobas e601, 4 cobas e602, and 4 cobas e801; overall Roche $CV_{\text{pooled}} = 11.7\%$), with 4 of these Roche instruments (3 cobas e411 and 1 cobas e801) > 10.0 % on the plasma sample at the US URL ($CV_{\text{pooled}} = 8.5\%$). The mean concentrations for the serum samples ranged from 7.8 to 10.2 ng/L for e411, 8.0–9.4 ng/L for e601, 7.5–9.9 ng/L for the e602,

8.0–10.1 for the e801 and for the plasma samples 9.9–12.5 ng/L for e411, 10.9–12.4 ng/L for the e601, 10.6–12.8 ng/L for e602, and 11.5–13.9 ng/L for e801. The highest observed imprecision was from an e411 instrument with a CV of 30.3 % for the plasma and 19.2 % for the serum samples (Fig. 2, Supplemental Table 2).

4. Discussion

The findings from this prospective multi-center evaluation of imprecision at the female URL indicates differences between hs-cTn assays at this important cutoff with not all instruments achieving a 10 % CV. These differences could result in clinical misclassification. One-third of the instruments measuring hs-cTnT did not meet this precision target at the female URL recommended for use outside of the US. This may be why there is more controversy in regard to the value of using sex specific thresholds to evaluate possible MI with hs-cTnT.

A sex-specific URL cutoff for the diagnosis of MI is recommended by the Universal Definition of Myocardial Infarction based on studies that consistently demonstrate that cTnI and cTnT concentrations are lower in females than males [10]. Prospective studies of consecutive patients rather than selected ones demonstrate use of hs-cTnI sex-specific URLs result in a similar proportion of male and female patients being identified with myocardial injury [11]. Implementation of sex-specific URLs in some studies increase the proportion of female patients with myocardial injury [12]. The data with hs-cTnT is more mixed [13]. The retrospective nature of these studies meant female patients were not recognised with myocardial injury at the time of assessment as their cTnT concentrations were below the uniform URL used to guide care. Therefore, adoption of this guideline recommendation has been greater for sites using a hs-cTnI assay than for sites using a hs-cTnT assay [14]. This issue may also be important for the use of a single sample to exclude acute MI where the lower values in females present a more critical issue in regard to imprecision. This may be why studies often identify women as those in whom a rule-out strategy based on a single measurement may be less effective [15].

The CODE-MI trial is a stepped wedge, cluster randomized trial which aims to understand the impact of using a female-specific URL for all hs-cTn assays on the diagnosis, treatment, and outcomes of women with possible MI [6]. Based on our findings of assay imprecision here, it will be important to evaluate whether the impact of implementing a female specific 99th-percentile URL differs in those sites where the

instrument performance did not meet the recommendations for a CV ≤ 10 %. Imprecision at this cutoff could result in over or under investigation at these sites.

Whilst our study is the first prospective, multi-center evaluation of assay imprecision at the female URL there are some limitations that merit consideration. First, there was unequal representation between instrument types and number of tests performed and thus it is difficult to assess those differences. Second, different sites had different instruments so the impact of the environment on the imprecision observed across the various instruments is unclear. Third, despite providing detailed instructions on handling and testing the aliquots, errors may have occurred which could have contributed to imprecision. Finally, a larger study is required to assess daily imprecision at the female URL.

In summary, this year long monthly testing prospective study highlights that not all assays and instruments consistently achieve the necessary precision required for accurate reporting of hs-cTn at the guideline recommended female URL cutoff.

Conflict of Interest / Disclosures:

Dr. Kavsak has received grants/reagents/consultant/advisor/ honoraria from Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Ortho Clinical Diagnostics, Quidel, Randox Laboratories, Roche Diagnostics, Siemens Healthcare Diagnostics, and Thermo Fisher Scientific. McMaster University has the following patent with Drs. Kavsak and Worster listed as inventors “METHOD OF DETERMINING RISK OF AN ADVERSE CARDIAC EVENT”. McMaster University has also filed the following patent: “QUALITY CONTROL MATERIALS FOR CARDIAC TROPONIN TESTING” with Dr. Kavsak and Ms. Clark being listed as inventors. Dr Mills has received research grants awarded to the University of Edinburgh from Abbott Diagnostics, Siemens Healthineers and Roche Diagnostics outside the submitted work, and honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, LumiraDx and Psyros Diagnostics. Dr. Yip has received research support from Roche Diagnostics. Dr. Thiruganasambandamoorthy has received grant funds from The Physicians’ Services Incorporated Foundation, Canadian Institutes of Health Research, Heart and Stroke Foundation Canada, The Ottawa Hospital Academic Medical Organization (TOHAMO), Ontario Centre of Innovation (OCI), and the Cardiac Arrhythmia Network of Canada (SRG-15-P10-001) as part of the Networks of Centres of Excellence (NCE). Dr. Thiruganasambandamoorthy is currently supported




Fig. 1. The imprecision (circles representing %CV) for the Abbott hs-cTnI assay (Alinity, ARCHITECT i1000, ARCHITECT i2000), the Beckman hs-cTnI assay (Access 2, Dxl 600, Dxl 800) and the Siemens hs-cTnI assay (Atellica) at the Female URL (16 ng/L, 12 ng/L, 39 ng/L, respectively). The dashed line is the 10 %CV.




Fig. 2. The imprecision (circles representing %CV) for the Roche hs-cTnT assay with serum (black circles) at the Outside the United States (US) URL (9 ng/L) and with plasma (grey circles) at the US URL (14 ng/L) for the cobas e411, e601, e602 and e801. The dashed line is the 10 %CV.

through a University of Ottawa Tier-1 Clinical Research Chair in Cardiovascular Emergencies award. Dr. Taher received in-kind funding from Roche for an unrelated project. Dr. Belley-Cote has received grants from Bayer, BMS-Pfizer, Roche Diagnostics and Abbott, and consulting fees from Trimed Therapeutics. Dr. Jaffe consults presently or has in the past consulted for most of the major diagnostic companies and Moderna. He also has equity in RCE Technologies. Dr. Aakre has served on advisory board for Roche Diagnostics and SpinChip, consultant honoraria form CardiNor, lecturing honorarium from Siemens Healthineers and Snibe Diagnostics and research grants from Siemens Healthineers and Roche Diagnostics. She is Associate Editor of Clinical Biochemistry and Chair of the IFCC Committee of Clinical Application of Cardiac Biomarkers.

Funding/Support:

Grant from the Canadian Institutes of Health Research (Kavsak). Chair Award, Programme Grant, and Research Excellence Award (CH/F/21/90010, RG/20/10/34966, RE/18/5/34216) from the British Heart Foundation (Mills).

Role of Sponsor:

The funding organizations had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data, or in the final approval of the manuscript.

CRedit authorship contribution statement

Peter A. Kavsak: Conceptualization, Funding acquisition, Data curation, Writing – original draft, Formal analysis, Methodology, Supervision, Resources, Project administration, Software. **Lorna Clark:** Data curation, Writing – review & editing, Methodology. **Saranya Arnoldo:** Writing – review & editing, Resources. **Amy Lou:** Writing – review & editing, Resources. **Jennifer L. Shea:** Writing – review & editing, Resources. **Shaun Eintracht:** Writing – review & editing, Resources. **Andrew W. Lyon:** Writing – review & editing, Resources. **Vipin Bhayana:** Writing – review & editing, Resources. **Laurel Thorlacius:** Writing – review & editing, Resources. **Joshua E. Raizman:** Writing – review & editing, Resources. **Albert Tsui:** Writing – review & editing, Resources. **Rose Djiana:** Writing – review & editing, Resources.

Michael Chen: Writing – review & editing, Resources. **Yun Huang:** Writing – review & editing, Resources. **Ali Haider:** Writing – review & editing, Resources. **Ronald A. Booth:** Writing – review & editing, Resources. **Chris McCudden:** Writing – review & editing, Resources. **Paul M. Yip:** Writing – review & editing, Resources. **Daniel Beriault:** Writing – review & editing, Resources. **David Blank:** Writing – review & editing, Resources. **Angela W.S. Fung:** Writing – review & editing, Resources. **Jennifer Taher:** Writing – review & editing, Resources. **Julie St-Cyr:** Writing – review & editing, Resources. **Sameer Sharif:** Writing – review & editing. **Emilie Belley-Cote:** Writing – review & editing. **Beth L. Abramson:** Writing – review & editing. **Steven M. Friedman:** Writing – review & editing. **Jafna L. Cox:** Writing – review & editing. **Marco L.A. Sivilotti:** Writing – review & editing. **Annabel Chen-Tournoux:** Writing – review & editing. **Jesse McLaren:** Writing – review & editing. **Susanna Mak:** Writing – review & editing. **Venkatash Thiruganasambandamoorthy:** Writing – review & editing. **Frank Scheuermeyer:** Writing – review & editing. **Andrew Worster:** Writing – review & editing. **Dennis Ko:** Writing – review & editing. **Karin H. Humphries:** Writing – review & editing. **Kristin M. Aakre:** Writing – review & editing. **Nicholas L. Mills:** Writing – review & editing. **Allan S. Jaffe:** Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no other/known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Grant from the Canadian Institutes of Health Research (Kavsak). Special thanks for the following individuals who helped in this prospective study: Chantele Roy, Paul Malinowski, Tara Bryce (CRLB-GMEL, Hamilton Health Sciences, Hamilton, ON) Nadia Caruso (Juravinski Hospital and Cancer Centre, Hamilton ON), Vathany Kulasingam (University Health Network, Toronto, ON), Mark Cheung (Sunnybrook Hospital, Toronto, ON), Viktor Skihar (Regina General Hospital, Regina, SK), Joshua Buse (Regina General Hospital, Regina, SK), Janet Simons (St. Paul's Hospital, Vancouver, BC), Barry Hoffman (Mount Sinai Hospital, Toronto, ON), Joël Lavoie (Institut de Cardiologie de Montréal, Montréal, QC, Canada), Laura Burns (St. Paul's Hospital, Vancouver,

BC), Allyse Hummelman (Mount Saint Joseph Hospital, Vancouver, BC), Jennifer Annand (Victoria General Hospital & Royal Jubilee Hospital, Victoria, BC), Robyn Dahl (Victoria General Hospital, Victoria, BC), Sabrina Hocken (Victoria General Hospital, Victoria, BC), Marisa Schneider (Royal Jubilee Hospital, Victoria, BC), Maryann Jiang (Royal Jubilee Hospital, Victoria, BC), Darryl Holden (Royal Jubilee Hospital, Victoria, BC), Krista McComb (University of Alberta Hospital (UAH), Edmonton, AB), Eric (Phong) Ly (University of Alberta Hospital (UAH), Edmonton, AB), Carmen Zimmer (University of Alberta Hospital (UAH), Edmonton, AB), Christina Gauvreau (University of Alberta Hospital (UAH), Edmonton, AB), Jan Feser (Regina General Hospital, Regina, SK), Rob Saunders (St. Paul's Hospital, Saskatoon, SK), Connie Neuberger (Royal University Hospital, Saskatoon, SK), Karen Nogier (Royal University Hospital, Saskatoon, SK), Kari Henwood (St. Boniface Hospital, Winnipeg, MB), Jeffrey Noel (St. Boniface Hospital, Winnipeg, MB), JoAnne Novakowski (St. Boniface Hospital, Winnipeg, MB), Debbie Kiel (Selkirk Regional Health Centre, Selkirk, MB), Meghan Rasmussen (Selkirk Regional Health Centre, Selkirk, MB), Katie Ndukwu (Health Sciences Centre, Winnipeg, MB), Steven Cong (Health Sciences Centre, Winnipeg, MB), Roy Augustin (Mount Sinai Hospital, Toronto, ON), Fari Rokhforooz (Mount Sinai Hospital, Toronto, ON), Bonny Lem Ragosnig (Sunnybrook Hospital, Toronto, ON), Liyan Ma (Sunnybrook Hospital, Toronto, ON), Sarah Lam (Toronto General Hospital (UHN), Toronto, ON), Julia Shao (St. Michael's Hospital, Toronto, ON), Robert Dean (Kingston General Hospital, Kingston, ON), Leanne Reilly (Kingston General Hospital, Kingston, ON), Emma Greenough (Ottawa Hospital - Civic Campus, Ottawa, ON), Sarah Cascanette (Ottawa Hospital - General Campus, Ottawa, ON), Janette Rutledge (Ottawa Hospital - General Campus, Ottawa, ON), Isla Craig (Ottawa Hospital - Civic Campus, Ottawa, ON), Alan Burgess (Ottawa Hospital - Civic Campus, Ottawa, ON), Guylaine Imbeault (Ottawa Hospital - General Campus, Ottawa, ON), Sandy Bookalam (Ottawa Hospital - General Campus, Ottawa, ON), Purvi Patel (Brampton Civic Hospital, Brampton ON), Linda Stevenson (Etobicoke General Hospital, Etobicoke, ON), Lisa Brown (Peel Memorial Centre for Integrated Health and Wellness, Brampton, ON), Husam Abdoh (LHSC - Victoria Hospital, London, ON), Bill Richardson (LHSC - University Hospital, London, ON), Kylie McInerney (LHSC - University Hospital, London, ON), Rick Moore (LHSC - University Hospital, London, ON), Nathalie Payette (Montreal General Hospital, Montréal, QC), Gloria Marcaida (Montreal General Hospital, Montréal, QC), Kruno Lorkovic (Montreal General Hospital, Montréal, QC), Maryse Coderre (Montreal General Hospital, Montréal, QC), Lisa Murphy (McGill University Health Centre, Glen Site Montréal, QC), Maia Stallone (McGill University Health Centre, Glen Site, Montréal, QC), Ana Marcaida (McGill University Health Centre, Glen Site, Montréal, QC), Micheline Masangya (St. Mary's Hospital Center, Montréal, QC), Youcef Amimer (Institut de Cardiologie de Montréal, Montréal, QC), Rianne Madriaga (Jewish General Hospital, Montréal, QC), Oktavian Toka (Jewish General Hospital, Montréal, QC), Safiya Sweeney (Jewish General Hospital, Montréal, QC), Girupan Arasaratman (Jewish General Hospital, Montréal, QC), Ashley Stevens (Saint John Regional Hospital, Saint John, NB), Tiffany Moore (Saint John Regional Hospital, Saint John, NB), Christina Quondam Franks (Saint John Regional Hospital, Saint John, NB), Ian MacLean (Queen Elizabeth II Health Sciences Centre , Halifax, NS), Sandy Schlay (Queen Elizabeth II Health Sciences Centre , Halifax, NS), Kathleen Lawrence (Dartmouth General Hospital, Dartmouth, NS), Kelly Smith (Dartmouth General Hospital, Dartmouth, NS), Rose Bartlett (Cobequid Community Health Centre, Lower Sackville, NS), Craig Leblanc (Cobequid Community Health Centre, Lower Sackville, NS), Kimberly Ross (Hants Community Hospital, Windsor, NS), Shelley Strong (Cobequid Community Health Centre, Lower Sackville, NS), Shannah Hynes (Cobequid Community Health Centre, Lower Sackville, NS), Jenilee Calbury (Hants Community Hospital, Windsor, NS), Rebecca Reid (Queen Elizabeth II Health Sciences Centre , Halifax, NS), Trish Jarvie (Hamilton General Hospital, Hamilton, ON), Jill Boreyko (Hamilton General Hospital, Hamilton, ON), Ronda Snowdy

(Hamilton General Hospital, Hamilton, ON), Binal Parikhb (Hamilton General Hospital, Hamilton, ON), Trisha Bellamy (Hamilton General Hospital, Hamilton, ON), Ching Mark (Juravinski Hospital and Cancer Centre, Hamilton, ON), Elspeth Millar (Juravinski Hospital and Cancer Centre, Hamilton, ON), Brian Vandermeij (Juravinski Hospital and Cancer Centre, Hamilton, ON), Leesa Lillie (Juravinski Hospital and Cancer Centre, Hamilton, ON), Matthew Hulett (West Lincoln Memorial Hospital, Grimsby, ON), Glen Edmunds (West Lincoln Memorial Hospital, Grimsby, ON) and the CODE-MI study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.clinbiochem.2024.110731>.

References

- [1] J.S. Alpert, K. Thygesen, E. Antman, J.P. Bassand, Myocardial infarction redefined—a consensus document of the joint European society of cardiology/american college of cardiology committee for the redefinition of myocardial infarction, *J. Am. Coll. Cardiol.* 36 (3) (2000) 959–969.
- [2] P.A. Kavsak, A.R. MacRae, M.J. Yerna, A.S. Jaffe, Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury, *Clin. Chem.* 55 (3) (2009 Mar) 573–577.
- [3] A.H.B. Wu, R.H. Christenson, D.N. Greene, et al., Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the academy of the american association for clinical chemistry and the task force on clinical applications of cardiac bio-markers of the international federation of clinical chemistry and laboratory medicine, *Clin. Chem.* 64 (2018) 645–655.
- [4] K.M. Aakre, A.K. Saenger, R. Body, P. Collinson, O. Hammarsten, A.S. Jaffe, P. Kavsak, T. Omland, J. Ordonez-Lianos, F.S. Apple, Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC committee on clinical application of cardiac bio-markers, *Clin. Chem.* 68 (8) (2022) 1022–1030.
- [5] A.S. Shah, A. Anand, Y. Sandoval, K.K. Lee, S.W. Smith, P.D. Adamson, A. R. Chapman, T. Langdon, D. Sandeman, A. Vaswani, F.E. Strachan, A. Ferry, A. G. Stürzaker, A. Reid, A.J. Gray, P.O. Collinson, D.A. McAllister, F.S. Apple, D. E. Newby, N.L. Mills, High-STEACS investigators. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study, *Lancet* 386 (10012) (2015) 2481–2488.
- [6] Y. Zhao, M. Izadnegahdar, M.K. Lee, et al., High-sensitivity cardiac troponin—optimizing the diagnosis of acute myocardial infarction/injury in women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial, *Am. Heart J.* 229 (2020) 18–28.
- [7] P.A. Kavsak, N. Caruso, J. Beattie, L. Clark, Centrifugation—an important pre-analytical factor for the Abbott Architect high-sensitivity cardiac troponin I assay, *Clin. Chim. Acta* 436 (2014) 273–275.
- [8] P.A. Kavsak, K. MacEachern, E. Petrayeva, L. Clark, Long-term quality control testing on a high-sensitivity cardiac troponin I assay, *Clin. Chim. Acta* 498 (2019) 27–29.
- [9] P.A. Kavsak, L. Clark, S. Arnoldo, A. Lou, J.L. Shea, S. Eintracht, A.W. Lyon, V. Bhayana, L. Thorlacius, J.E. Raizman, A.K.Y. Tsui, R. Djiana, M. Chen, Y. Huang, R.A. Booth, C. McCudden, J. Lavoie, D.R. Berault, D.W. Blank, A.W.S. Fung, B. Hoffman, J. Taher, J. St-Cyr, P.M. Yip, E.P. Belle-Cote, B.L. Abramson, B. Borgundvaag, S.M. Friedman, S. Mak, J. McLaren, B. Steinhart, J.A. Udell, H. C. Wijesundera, P. Atkinson, S.G. Campbell, K. Chandra, J.L. Cox, S. Mulvagh, A. U. Quraishi, A. Chen-Tournoux, G. Clark, E. Segal, N. Suskin, A.M. Johri, M.L. A. Sivilotti, H. Garuba, V. Thiruganasambandamoorthy, S. Robinson, F. Scheuermeyer, K.H. Humphries, M. Than, J.W. Pickering, A. Worster, N.L. Mills, P.J. Devereaux, A.S. Jaffe, Analytic result variation for high-sensitivity cardiac troponin: interpretation and consequences, *Can. J. Cardiol.* 39 (7) (2023) 947–951.
- [10] K. Thygesen, J.S. Alpert, A.S. Jaffe, B.R. Chaitman, J.J. Bax, D.A. Morrow, H. D. White, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018), *Circulation* 138 (20) (2018) e618–e651.
- [11] A.S. Shah, M. Griffiths, K.K. Lee, D.A. McAllister, A.L. Hunter, A.V. Ferry, A. Cruickshank, A. Reid, M. Stoddart, F. Strachan, S. Walker, P.O. Collinson, F. S. Apple, A.J. Gray, K.A. Fox, D.E. Newby, N.L. Mills, High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study, *BMJ* 21 (350) (2015) g7873.
- [12] K.K. Lee, A.V. Ferry, A. Anand, F.E. Strachan, A.R. Chapman, D.M. Kimenai, S.J. R. Meex, C. Berry, I. Findlay, A. Reid, A. Cruickshank, A. Gray, P.O. Collinson, F. S. Apple, D.A. McAllister, D. Maguire, K.A.A. Fox, D.E. Newby, C. Tuck, C. Keerie, C.J. Weir, A.S.V. Shah, N.L. Mills, H-STEACS Investigators, Sex-specific thresholds of high-sensitivity troponin in patients with suspected acute coronary syndrome, *J. Am. Coll. Cardiol.* 74 (16) (2019) 2032–2043.
- [13] M. Rubini Giménez, R. Twerenbold, J. Boeddinghaus, T. Nestelberger, C. Puelacher, P. Hillinger, K. Wildi, C. Jaeger, K. Grimm, K.F. Heitzelmann,

- Z. Sabti, P. Badertscher, J. Cupa, U. Honegger, N. Schaerli, N. Kozhuharov, J. du Fay de Lavallaz, B. Lopez, E. Salgado, Ò. Miró, F.J. Martín-Sánchez, E.R. Adrada, B. Morawiec, J. Parenica, E. Ganovska, C. Neugebauer, K. Rentsch, J. Lohrmann, S. Osswald, T. Reichlin, C. Mueller, Clinical Effect of Sex-Specific Cutoff Values of High-Sensitivity Cardiac Troponin T in Suspected Myocardial Infarction, *JAMA Cardiol.* 1 (8) (2016) 912–920.
- [14] A. Anand, A.S.V. Shah, A. Beshiri, A.S. Jaffe, N.L. Mills, Global adoption of high-sensitivity cardiac troponins and the universal definition of myocardial infarction, *Clin. Chem.* 65 (3) (2019) 484–489.
- [15] Y. Sandoval, B.R. Lewis, R.A. Mehta, O. Ola, J.D. Knott, L. De Michieli, A. Akula, R. Lobo, E.H. Yang, S.M. Gharacholou, M. Dworak, E. Crockford, N. Rastas, E. Grube, S. Karturi, S. Wohlrab, D.O. Hodge, T. Tak, C. Cagin, R. Gulati, A.S. Jaffe, Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation, *Circulation* 145 (23) (2022) 1708–1719.